These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11877267)

  • 1. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
    Kakkar VV; Hoppenstead DA; Fareed J; Kadziola Z; Scully M; Nakov R; Breddin HK
    Blood; 2002 Mar; 99(6):1965-70. PubMed ID: 11877267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
    Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV
    Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
    Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
    JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
    Wellington K; McClellan K; Jarvis B
    Drugs; 2001; 61(8):1185-209. PubMed ID: 11465877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
    Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
    Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
    Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Elliott G; Stein PD; Gottschalk A; Valentine KA; Mah AF
    Arch Intern Med; 2000 Jan; 160(2):229-36. PubMed ID: 10647762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    van der Heijden JF; Hutten BA; Büller HR; Prins MH
    Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Khasanova ZB; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(12):43-8. PubMed ID: 22416444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current management of acute symptomatic deep vein thrombosis.
    Heit JA
    Am J Cardiovasc Drugs; 2001; 1(1):45-50. PubMed ID: 14728051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.